DAGPE: Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism

Sponsor
Franciscus Gasthuis (Other)
Overall Status
Recruiting
CT.gov ID
NCT06043726
Collaborator
(none)
230
1
28
8.2

Study Details

Study Description

Brief Summary

Introduction:

The diagnosis of pulmonary embolism (PE) is a challenge in the Emergency Department. D-dimer based diagnostic algorithms for PE have a very high sensitivity, but rely upon a vast amount of CT angiography and potentially unnecessary exposure to radiation. An accurate diagnostic algorithm that does not involve d-dimer testing might reduce this burden.

An abnormal Alveolar-arterial oxygen gradient (A-a gradient) seems to increase the chance of PE. However, a normal A-a gradient on its own does not exclude the diagnosis. In this paper, the accuracy of A-a gradient testing and a combination of Years criteria with A-a gradient testing will be assessed.

Methods:

This is a prospective, single center, observational study. All patients that present at our emergency department from September 2022 until September 2023 with a suspicion of pulmonary embolism will be analyzed for eligibility and included in the study after informed consent. The aim is to include at least 230 patients in the study.

Analysis: The primary outcome is the diagnostic accuracy of a YEARS and A-a gradient based algorithm for pulmonary embolism. The secondary outcome is the potential decrease in performed imaging in order to exclude pulmonary embolism.

Valorisation An accurate A-a gradient-based algorithm for pulmonary embolism in low risk patients will be a step towards an improved clinical risk score. We aim to reduce the amount of diagnostic imaging, i.e. CT-angiography. Meaning less, potentially unnecessary, exposure to radiation for the patient. Furthermore, it could lower healthcare costs by reducing expensive diagnostic imaging.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Laboratory testing: D-dimeer and astrup

Study Design

Study Type:
Observational
Anticipated Enrollment :
230 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Diagnostic Accuracy of Arterial-alveolar Oxygen Gradient in Low Risk Patients With Suspected Pulmonary Embolism
Actual Study Start Date :
Sep 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2023
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Suspected PE

Patients with suspected pulmonary embolism

Diagnostic Test: Laboratory testing: D-dimeer and astrup
Standard care: Laboratory result (D-dimer and astrup). CT scan for pulmonary embolism if indicated
Other Names:
  • CT-scan for pulmonary embolism
  • Outcome Measures

    Primary Outcome Measures

    1. Diagnostic accuracy of a combination of a normal Alveolar-Arterial Oxygen Gradient with negative YEARS criteria in patients with suspected pumonary embolism [At submission in the Emergency Department]

    Secondary Outcome Measures

    1. How many CT-scans would have been avoided if the algorithm was used in normal practice [At submission in the Emergency Department]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    N/A and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • Patient with suspected pulmonary embolism

    • Emergency department D-dimer result available

    • Arterial blood gas available

    Exclusion Criteria:
    • Patients without documented oxygen suppletion durig blood gas measurement

    • Patients without documented and insufficient data to calculate YEARS criteria

    • Pregnancy

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Franciscus Gasthuis Rotterdam Netherlands

    Sponsors and Collaborators

    • Franciscus Gasthuis

    Investigators

    • Study Chair: Sander Mol, Franciscus Gasthuis

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    Responsible Party:
    Franciscus Gasthuis
    ClinicalTrials.gov Identifier:
    NCT06043726
    Other Study ID Numbers:
    • 2021-040
    First Posted:
    Sep 21, 2023
    Last Update Posted:
    Sep 21, 2023
    Last Verified:
    Sep 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Franciscus Gasthuis
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Sep 21, 2023